A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

"Induction stage：Adebrelimab+TC： Adebrelimab : 1200mg d1, iv, q3w ； TC : paclitaxel 135mg/m2, or nab-paclitaxel paclitaxel 180mg/m2, d1, iv，carboplatin AUC=5, d1, iv, q3w，2 cycles.~Treatment stage: TC/PF+ radiation therapy:~PET-CT responders (SUV (PETr) reduction ≥35%)：~TC/PF+ radiation therapy:~TC : paclitaxel 50mg/m2, nab-paclitaxel paclitaxel 60mg/m2, d1, iv; carboplatin AUC=2, d1, iv, qw，5 cycles.~PF : fluorouracil 750-1000mg/m2, CIV 96 hours，cisplatin 75mg/m2, d1, iv, q4w，2 cycles.~Radiation therapy: 50.4Gy-60Gy/28-33f.~PET-CT non-responders (SUV (PETr) reduction \<35%)：(switch to a different chemotherapy drug which not used during the earlier induction phase)~PF/TC+ radiation therapy:~dose same as above.~Maintenance stage: Adebrelimab:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs（Up to one year）."